Treatment-related complications
| . | Era A . | Era B . | Era C . | Era D . | ||||
|---|---|---|---|---|---|---|---|---|
| <1958 . | 1958-1975 . | 1976-1982 . | 1983-1992 . | |||||
| Severe . | Mild . | Severe . | Mild . | Severe . | Mild . | Severe . | Mild . | |
| Total N | 688 | 843 | 1542 | 787 | 1121 | 427 | 1548 | 530 |
| Viral infections (% positive) | ||||||||
| HBV | 70.5 | 33 | 71.7 | 34.4 | 38.4 | 9.1 | 5.2 | 2.4 |
| HCV | 92.3 | 54.2 | 93 | 60.6 | 84.4 | 33.3 | 32.6 | 6.2 |
| HBV and HCV coinfection | 69.2 | 27.9 | 61.2 | 31.5 | 34.2 | 6.1 | 3.7 | 0.4 |
| HIV | 42.9 | 4.7 | 61 | 11.9 | 26.2 | 4 | 1 | 0.2 |
| HIV and HCV coinfection | 42.2 | 4.2 | 59 | 10.8 | 23.3 | 3.7 | 0.7 | 0 |
| Not infected with HIV, HBV, or HCV | 5.5 | 40.7 | 4.1 | 35.8 | 10.4 | 63.7 | 65.4 | 91.5 |
| Ever received therapy for chronic viral hepatitis | ||||||||
| Any therapy (% of total infected HCV) | 29.0 | 33.0 | 32.7 | 36.9 | 24.2 | 29.6 | 26.7 | 33.3 |
| Sustained virulogic response (% of total infected HCV) | 9.3 | 10.1 | 10.4 | 16.4 | 9.6 | 10.5 | 8.7 | 18.3 |
| Hepatitis morbidity (%) | ||||||||
| Chronically elevated ALT/AST | 29.6 | 16.7 | 29.8 | 16.9 | 17 | 7.7 | 5.6 | 2.4 |
| Signs or symptoms of liver disease | 8 | 3.2 | 6.2 | 3.8 | 2 | 0.2 | 0.2 | 0 |
| Inhibitor development | ||||||||
| Any inhibitor recorded | 17.0 | 3.3 | 13.6 | 3.6 | 11.5 | 2.8 | 15.6 | 2.8 |
| . | Era A . | Era B . | Era C . | Era D . | ||||
|---|---|---|---|---|---|---|---|---|
| <1958 . | 1958-1975 . | 1976-1982 . | 1983-1992 . | |||||
| Severe . | Mild . | Severe . | Mild . | Severe . | Mild . | Severe . | Mild . | |
| Total N | 688 | 843 | 1542 | 787 | 1121 | 427 | 1548 | 530 |
| Viral infections (% positive) | ||||||||
| HBV | 70.5 | 33 | 71.7 | 34.4 | 38.4 | 9.1 | 5.2 | 2.4 |
| HCV | 92.3 | 54.2 | 93 | 60.6 | 84.4 | 33.3 | 32.6 | 6.2 |
| HBV and HCV coinfection | 69.2 | 27.9 | 61.2 | 31.5 | 34.2 | 6.1 | 3.7 | 0.4 |
| HIV | 42.9 | 4.7 | 61 | 11.9 | 26.2 | 4 | 1 | 0.2 |
| HIV and HCV coinfection | 42.2 | 4.2 | 59 | 10.8 | 23.3 | 3.7 | 0.7 | 0 |
| Not infected with HIV, HBV, or HCV | 5.5 | 40.7 | 4.1 | 35.8 | 10.4 | 63.7 | 65.4 | 91.5 |
| Ever received therapy for chronic viral hepatitis | ||||||||
| Any therapy (% of total infected HCV) | 29.0 | 33.0 | 32.7 | 36.9 | 24.2 | 29.6 | 26.7 | 33.3 |
| Sustained virulogic response (% of total infected HCV) | 9.3 | 10.1 | 10.4 | 16.4 | 9.6 | 10.5 | 8.7 | 18.3 |
| Hepatitis morbidity (%) | ||||||||
| Chronically elevated ALT/AST | 29.6 | 16.7 | 29.8 | 16.9 | 17 | 7.7 | 5.6 | 2.4 |
| Signs or symptoms of liver disease | 8 | 3.2 | 6.2 | 3.8 | 2 | 0.2 | 0.2 | 0 |
| Inhibitor development | ||||||||
| Any inhibitor recorded | 17.0 | 3.3 | 13.6 | 3.6 | 11.5 | 2.8 | 15.6 | 2.8 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.